Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology
5-year Overall Survival Rates by Stage at Presentation | Download Scientific Diagram
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
4baseCare on Twitter: "Research data suggests that 5-year survival rates in different subtypes of Cholangiocarcinoma vary in different stages of the disease. LINK: https://t.co/yh5Cbkcr1j #MedTwitter https://t.co/nhmwIeZAg9" / Twitter
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal
Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
Efficacy for Newly Diagnosed Glioblastoma (GBM) | Optune®
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/4-Figure1-1.png "PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar")
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
5-year overall survival rates of Different Tumor Stages. After Log-rank... | Download Scientific Diagram
Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database | BMC Cancer | Full Text
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
Efficacy Results | Myelofibrosis Clinical Trials | Jakafi HCP
Overall survival. a The 5-year overall survival (OS) was 64.9%. b The... | Download Scientific Diagram
Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma
This figure shows the 5-year overall survival (OS) in 250 synovial... | Download Scientific Diagram
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
